OncoMatch/Clinical Trials/NCT06248606
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Is NCT06248606 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Adagrasib for non small cell lung cancer.
Treatment: Adagrasib — This is a single arm phase 2 trial is to evaluate the efficacy of SRS plus adagrasib for the treatment of brain metastases for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). A total of 30 patients will be enrolled on this study.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: KRAS g12c
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: KRAS G12C tyrosine kinase inhibitor
Prior treatment with KRAS G12C tyrosine kinase inhibitor.
Lab requirements
Blood counts
Hemoglobin (Hgb): ≥ 8.0 g/dL in the absence of transfusions within 7 days prior to testing.
Kidney function
Calculated creatinine clearance ≥ 60 mL/min
Liver function
Bilirubin ≤ 1.5 mg/dL; AST ≤ 3.0 × ULN; ALT ≤ 3.0 × ULN
Demonstrate adequate organ function as defined below. ... Hemoglobin (Hgb): ≥ 8.0 g/dL ... Calculated creatinine clearance: ≥ 60 mL/min ... Bilirubin: ≤ 1.5 mg/dL ... AST: ≤ 3.0 × ULN ... ALT: ≤ 3.0 × ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
- University of Virginia Health System · Charlottesville, Virginia
- Virginia Commonwealth University · Richmond, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify